HRO761: a First-in-Class Non-Covalent WRN Inhibitor with Synthetic Lethality in MSI Cancers

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Synfacts 2024; 20(09): 0988
DOI: 10.1055/s-0043-1773367

Innovative Drug Discovery and Development

Contributor(s):

Antonia F. Stepan (Roche)

,

Seong Heon Kim (Hyundai Pharm)

WRN - synthetic lethality - MSI cancers - non-covalent WRN inhibitor - first-in-class inhibitor - HRO761 - clinical candidates

Article published online:
16 August 2024

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany